Citicoline, Alzheimer's disease, and cognitive performance

Tagged:  

Studies from throughout the world that can help you live longer

Citicoline(CDP-choline)is an endogenous intermediate in the formation of structural cell membrane phospholipids and acetylcholine in the brain. Citicoline has been extensively used for the treatment of neurodegenerative disorders associated with head trauma, stroke brain aging, cerebrovascular pathology, and Alzheimer's disease (AD). A 12 week study investigated the efficacy and safety of the treatment with 1,000 mg/day of citicoline vs. placebo in 30 individuals with Alzheimer disease (age 57-87 years) with mild to moderate senile dementia of the Alzheimer type. Results showed citicoline improved cognitive performance in those with Alzheimer's disease and this improvement on cognition was more pronounced in those with mild dementia. Citicoline also increased cerebral blood flow velocities in comparison with placebo; as well as diastolic velocity in the cerebral artery. Citicoline did not induce any adverse side effects or alterations in the blood. Thus, the data indicate that citicoline is well tolerated and improves cognitive performance, cerebral blood perfusion and the brain bioelectrical activity pattern in those with AD. Thus, citicoline might be a useful treatment in Alzheimer's disease. Its efficacy is greater in those with mild mental deterioration.

METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, Vol 21, Iss 9, pp 633-644

Share this with your friends